Why the study?
Redo surgical replacement for bioprosthetic valve dysfunction carries high mortality and morbidity, making transcatheter valve-in-valve procedures a preferred alternative in high-risk patients.
Is simultaneous transcatheter dual valve-in-valve implantation feasible and safe in a high-surgical-risk patient with failing bioprosthetic mitral and tricuspid valves?
Is simultaneous transcatheter dual valve-in-valve implantation feasible and safe in a high-surgical-risk patient with failing bioprosthetic mitral and tricuspid valves?
Answers are grounded in this paper and cite their sources.
Simultaneous transcatheter dual valve-in-valve replacement for failing mitral and tricuspid bioprostheses is a feasible and successful option for high-surgical-risk patients.
Background: Structural valve dysfunction in bioprosthetic heart valves necessitates redo replacement procedure that are associated with high mortality and morbidity. The transcatheter valve-in-valve (VIV) approach has emerged as a preferred option for patients requiring redo procedures due to structural valve degeneration. We report from India the first case of the simultaneous transcatheter dual VIV implantation (mitral valve and tricuspid valves) in a high-surgical-risk patient. Case summary: A 57-year-old female was presented with a history of rheumatic heart disease, post-mitral valve as well as tricuspid valve replacement (perimount 33 mm) 11 years back. Bioprosthetic heart valve was chosen probably due to limited life expectancy and compliance issues with monitoring of international normalised ratio (INR). She now presented with progressive dyspnoea, oedema, and palpitations (New York Heart Association Class III) for the last 6 months. The patient was scheduled for transcatheter dual valve replacement simultaneously. The procedure was successful with a favourable outcome, short hospital stays, and early recovery. Discussion: This is the first case of simultaneous transcatheter dual valve replacement reported from India, which is fluoroscopically guided and supported by TEE. It is a valuable and considerable option for patients with failing bioprosthesis valves who are at increased peri-operative risk.
No takes yet. Share an insight, caveat, or question.
Garg et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: